GLP-1 (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)

Catalog #: 028-09

Size: 200 µg

Price: $102

Ala
A

His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly

Molecular Weight: 4167.02
Purity: ≥ 95%
Validation: Exhibits correct molecular weight
Solubility: Soluble in water
Storage: Up to 6 months in lyophilized form at 0-5°C.
For best results, rehydrate just before use.
After rehydration, keep solution at +4°C for up to 5 days or freeze at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.

Appearance: White powder

Contents: Each vial contains 200 µg of NET peptide.

Structure:

Central Pre-proglucagon Peptides that Provide Opportunities for Treatment of Obesity

Abstract

GLP-1-directed NMDA receptor antagonism for obesity treatment

Abstract: The N-methyl-D-aspartate (NMDA) receptor is a glutamate-activated cation channel that is critical to many processes in the brain. Genome-wide association studies suggest that glutamatergic neurotransmission and NMDA receptor-mediated synaptic plasticity are important for body weight homeostasis1. Here we report the engineering and preclinical development of a bimodal molecule that integrates NMDA receptor antagonism with glucagon-like peptide-1 (GLP-1) receptor agonism to effectively reverse obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease. GLP-1-directed delivery of the NMDA receptor antagonist MK-801 affects neuroplasticity in the hypothalamus and brainstem. Importantly, targeting of MK-801 to GLP-1 receptor-expressing brain regions circumvents adverse physiological and behavioural effects associated with MK-801 monotherapy. In summary, our approach demonstrates the feasibility of using peptide-mediated targeting to achieve cell-specific ionotropic receptor modulation and highlights the therapeutic potential of unimolecular mixed GLP-1 receptor agonism and NMDA receptor antagonism for safe and effective obesity treatment.

Petersen J, Ludwig MQ, Juozaityte V, et al. GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature. 2024;629(8014):1133-1141. doi:10.1038/s41586-024-07419-8

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide.

OBJECTIVE: Glucagon-like peptide-1 (GLP-1) (7-36) amide is a glucoregulatory hormone with insulinotropic and insulinomimetic actions. We determined whether the insulinomimetic effects of GLP-1 are mediated through its principal metabolite, GLP-1 (9-36) amide (GLP-1m). METHODS AND PROCEDURES: Glucose turnover during two, 2-h, euglycemic clamps was measured in 12 lean and 12 obese (BMI <25 or >30 kg/m(2)) male and female subject volunteers with normal oral glucose tolerance test. Saline or GLP-1m were infused from 0 to 60 min in each study. Additionally, seven lean and six obese subjects underwent a third clamp in which the GLP-1 receptor (GLP-1R) antagonist, exendin (9-39) amide was infused from -60 to 60 min with GLP-1m from 0 to 60 min. RESULTS: No glucose infusion was required in lean subjects to sustain euglycemia (glucose clamp) during saline or GLP-1m infusions. However, in obese subjects glucose infusion was necessary during GLP-1m infusion alone in order to compensate for a marked (>50%) inhibition of hepatic glucose production (HGP). Plasma insulin levels remained constant in lean subjects but rose significantly in obese subjects after termination of the peptide infusions. During GLP-1R blockade, infusion of glucose was immediately required upon starting GLP-1m infusions in all subjects due to a more dramatic reduction in HGP, as well as a delayed and modest insulinotropic response. DISCUSSION: We conclude that GLP-1m potently inhibits HGP and is a weak insulinotropic agent. These properties are particularly apparent and pronounced in obese but only become apparent in lean subjects during GLP-1 (7-36) receptor blockade. These previously unrecognized antidiabetogenic actions of GLP-1m may have therapeutic usefulness.

Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring). 2008;16(7):1501-9

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.

Peptide hormones are secreted from endocrine cells and neurons and exert their actions through activation of G protein-coupled receptors to regulate a diverse number of physiological systems including control of energy homeostasis, gastrointestinal motility, neuroendocrine circuits, and hormone secretion. The glucagon-like peptides, GLP-1 and GLP-2 are prototype peptide hormones released from gut endocrine cells in response to nutrient ingestion that regulate not only energy absorption and disposal, but also cell proliferation and survival. GLP-1 expands islet mass by stimulating pancreatic beta-cell proliferation and induction of islet neogenesis. GLP-1 also promotes cell differentiation, from exocrine cells or immature islet progenitors, toward a more differentiated beta-cell phenotype. GLP-2 stimulates cell proliferation in the gastrointestinal mucosa, leading to expansion of the normal mucosal epithelium, or attenuation of intestinal injury in experimental models of intestinal disease. Both GLP-1 and GLP-2 exert antiapoptotic actions in vivo, resulting in preservation of beta-cell mass and gut epithelium, respectively. Furthermore, GLP-1 and GLP-2 promote direct resistance to apoptosis in cells expressing GLP-1 or GLP-2 receptors. Moreover, an increasing number of structurally related peptide hormones and neuropeptides exert cytoprotective effects through G protein-coupled receptor activation in diverse cell types. Hence, peptide hormones, as exemplified by GLP-1 and GLP-2, may prove to be useful adjunctive tools for enhancement of cell differentiation, tissue regeneration, and cytoprotection for the treatment of human disease.

Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17(2):161-71

Central pre-proglucagon derived peptides: opportunities for treatment of obesity.

Modern societies have moved from famine to feast and obesity and its co-morbidities now sweep the world as a global epidemic. Numerous scientific laboratories and pharmaceutical companies have taken the challenge and are now exploiting novel molecular targets for treatment of obesity. The pre-proglucagon system constitutes interesting candidates as potential targets for new anti-obesity drugs. In the periphery, pre-proglucagon derived peptides, Glucagon-Like Peptide-1 (GLP-1), Glucagon-Like Peptide-2 (GLP-2) and oxyntomodulin (OXM) are involved in a wide variety of physiological functions, including glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. Peripheral administration of GLP-1 derivatives and analogues to both rodents and man have shown promising effects on food intake and body weight suggesting that such therapies constitute potential anti-obesity treatment. In the central nervous system, pre-proglucagon and hence GLP-1, GLP-2 and OXM are exclusively found in a small population of nerve cells in the nucleus of the solitary tract. These constitute a neural pathway linking the “viscero-sensory” brainstem to hypothalamic nuclei involved in energy homeostasis. Intracerebroventricular administration of all of the three derived peptides robustly decrease food intake. It is evident that central GLP-1 agonism probably in combination with GLP-2 and/or OXM agonism constitute a potential pharmacological tool to reduce food intake and maybe also enhance energy expenditure. This and other aspects of the current state of the role of central pre-proglucagon in energy homeostasis are reviewed.

Larsen PJ, Vrang N, Tang-christensen M. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Curr Pharm Des. 2003;9(17):1373-82

Oxyntomodulin inhibits food intake in the rat.

Oxyntomodulin is derived from proglucagon processing in the intestine and the central nervous system. To date, no role in the central nervous system has been demonstrated. We report here that oxyntomodulin inhibits refeeding when injected intracerebroventricularly and into the hypothalamic paraventricular nucleus of 24-h fasted rats [intracerebroventricularly and into the paraventricular nucleus, 1 h, oxyntomodulin (1 nmol), 3.1 +/- 0.5 g; saline, 6.2 +/- 0.4 g; P < 0.005]. In addition, oxyntomodulin inhibits food intake in nonfasted rats injected at the onset of the dark phase (intracerebroventricularly, 1 h: oxyntomodulin, 3 nmol, 1.1 +/- 0.19 g vs. saline, 2.3 +/- 0.2 g; P < 0.05). This effect of oxyntomodulin on feeding is of a similar time course and magnitude as that of an equimolar dose of glucagon-like peptide-1. Other proglucagon-derived products investigated [glucagon, glicentin (intracerebroventricularly, 3 nmol; into the paraventricular nucleus, 1 nmol), and spacer peptide-1 (intracerebroventricularly and into the paraventricular nucleus, 3 nmol)] had no effect on feeding at any time point examined. The anorectic effect of oxyntomodulin (intracerebroventricularly, 3 nmol; into the paraventricular nucleus, 1 nmol) was blocked when it was coadministered with the glucagon-like peptide-1 receptor antagonist, exendin-(9-39) (intracerebroventricularly, 100 nmol; into the paraventricular nucleus, 10 nmol). However, oxyntomodulin has a lower affinity for the glucagon-like peptide-1 receptor compared with glucagon-like peptide-1 (IC(50): oxyntomodulin, 8.2 nM; glucagon-like peptide-1, 0.16 nM). One explanation for this is that there might be an oxyntomodulin receptor to which exendin-(9-39) can also bind and act as an antagonist.

Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001;142(10):4244-50

The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.

The dorsomedial hypothalamic nucleus harbors leptin sensitive neurons and is intrinsically connected to hypothalamic nuclei involved in feeding behavior. However, it also receives ascending input from the visceroceptive neurons of the brainstem. We have identified a unique glucagon-like-peptide-2 containing neuronal pathway connecting the nucleus of the solitary tract with the dorsomedial hypothalamic nucleus. A glucagon-like-peptide-2 fiber plexus targets neurons expressing its receptor within the dorsomedial hypothalamic nucleus. Pharmacological and behavioral studies confirmed that glucagon-like-peptide-2 signaling is a specific transmitter inhibiting rodent feeding behavior and with potential long-term effects on body weight homeostasis. The glucagon-like-peptide-1 receptor antagonist, Exendin (9-39) is also a functional antagonist of centrally applied glucagon-like-peptide-2.

Tang-christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 2000;6(7):802-7

 

Schematics

Expression of the preproglucagon gene

glp precursor

sequence glucagon
sequence comparison glp
figure from Nature magazine GLP-1 NMDA receptor

Related Products

Catalog
Product
Size
Price
Buy Now
028-26
[Cys0]-GLP-1 (12-24) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-26
100 µg
Size:100 µg
$202
Price: $202
H-028-26
[Cys0]-GLP-1 (12-24) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Antibody
Catalog: H-028-26
100 µl
Size:100 µl
$368
Price: $368
028-25
GLP-1 (2-24) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-25
100 µg
Size:100 µg
$242
Price: $242
H-028-25
GLP-1 (2-24) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Antibody
Catalog: H-028-25
100 µl
Size:100 µl
$368
Price: $368
028-73
GLP-1 (28-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-73
200 µg
Size:200 µg
$119
Price: $119
028-75
GLP-1 (28-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-75
200 µg
Size:200 µg
$128
Price: $128
028-74
GLP-1 (32-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-74
200 µg
Size:200 µg
$107
Price: $107
028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-11
200 µg
Size:200 µg
$188
Price: $188
028-23
[pGlu0]-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-23
100 µg
Size:100 µg
$254
Price: $254
028-24
acetyl-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-24
100 µg
Size:100 µg
$254
Price: $254
H-028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Antibody
Catalog: H-028-11
50 µl
Size:50 µl
$435
Price: $435
FC3-028-23
[pGlu0]-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Cy3 Labeled
Catalog: FC3-028-23
1 nmol
Size:1 nmol
$583
Price: $583
FC3-028-24
acetyl-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Cy3 Labeled
Catalog: FC3-028-24
1 nmol
Size:1 nmol
$583
Price: $583
FC5-028-23
[pGlu0]-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Cy5 Labeled
Catalog: FC5-028-23
1 nmol
Size:1 nmol
$583
Price: $583
FC5-028-24
acetyl-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Cy5 Labeled
Catalog: FC5-028-24
1 nmol
Size:1 nmol
$583
Price: $583
EK-028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – EIA Kit
Catalog: EK-028-11
96 wells
Size:96 wells
$564
Price: $564
EK-028-11CE
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – EIA Kit, CE Mark Certified
Catalog: EK-028-11CE
96 wells
Size:96 wells
$593
Price: $593
FG-028-11A
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – FAM Labeled
Catalog: FG-028-11A
1 nmol
Size:1 nmol
$334
Price: $334
FG-028-23A
[pGlu0]-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – FAM Labeled
Catalog: FG-028-23A
1 nmol
Size:1 nmol
$334
Price: $334
FG-028-24A
acetyl-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – FAM Labeled
Catalog: FG-028-24A
1 nmol
Size:1 nmol
$334
Price: $334
FEK-028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Fluorescent EIA Kit
Catalog: FEK-028-11
96 wells
Size:96 wells
$564
Price: $564
T-028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – I-125 Labeled
Catalog: T-028-11
10 µCi
Size:10 µCi
$1,136
Price: $1,136
T-028-23
[pGlu0]-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – I-125 Labeled
Catalog: T-028-23
10 µCi
Size:10 µCi
$1,136
Price: $1,136
T-028-24
acetyl-GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – I-125 Labeled
Catalog: T-028-24
10 µCi
Size:10 µCi
$1,136
Price: $1,136
T-G-028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – I-125 Labeled Purified IgG
Catalog: T-G-028-11
10 µCi
Size:10 µCi
$1,136
Price: $1,136
FR-028-11
GLP-1 (7-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Rhodamine Labeled
Catalog: FR-028-11
1 nmol
Size:1 nmol
$334
Price: $334
028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-13
200 µg
Size:200 µg
$188
Price: $188
H-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Antibody
Catalog: H-028-13
50 µl
Size:50 µl
$198
Price: $198
B-G-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Biotin Labeled Purified IgG
Catalog: B-G-028-13
100 µl
Size:100 µl
$865
Price: $865
FG-028-13A
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – FAM Labeled
Catalog: FG-028-13A
1 nmol
Size:1 nmol
$334
Price: $334
T-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – I-125 Labeled
Catalog: T-028-13
10 µCi
Size:10 µCi
$1,136
Price: $1,136
T-G-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – I-125 Labeled Purified IgG
Catalog: T-G-028-13
10 µCi
Size:10 µCi
$1,136
Price: $1,136
G-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Purified IgG Antibody
Catalog: G-028-13
400 µg
Size:400 µg
$435
Price: $435
FR-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – Rhodamine Labeled
Catalog: FR-028-13
1 nmol
Size:1 nmol
$334
Price: $334
RK-028-13
GLP-1 (7-37) (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine) – RIA Kit
Catalog: RK-028-13
125 tubes
Size:125 tubes
$924
Price: $924
028-12
GLP-1 (9-36) amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-12
200 µg
Size:200 µg
$198
Price: $198
028-09
GLP-1 (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-09
200 µg
Size:200 µg
$102
Price: $102
028-07
GLP-1 amide (Human, Rat, Mouse, Porcine, Bovine, Canine, Ovine)
Catalog: 028-07
200 µg
Size:200 µg
$188
Price: $188
029-10
GLP-1 analogue, C-terminal penicillamine-conjugated
Catalog: 029-10
100 ug
Size:100 ug
$305
Price: $305
001-18
GLP-1 Enhancer, N55
Catalog: 001-18
100 µg
Size:100 µg
$401
Price: $401
028-99
GLP-1-MK-801
Catalog: 028-99
100 ug
Size:100 ug
$315
Price: $315